C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics is a clinical-stage biotech pioneering targeted protein degradation (TPD) via its TORPEDO® platform, with pipeline assets targeting oncology indications that could unlock a differentiated mechanism in a large addressable market. Analyst conviction is exceptionally high — 7 Buy ratings with zero Hold or Sell — and the consensus price target of $13.33 implies over 250% upside from current levels, suggesting the market has significantly discounted the platform's potential. The key risk is the company's pre-profitability status and -15% revenue decline, which reflect clinical-stage binary event risk and dependence on partnership or milestone revenues to fund operations.

• Clinical data readouts from lead degrader programs (e.g., CFT8634 in SMARCB1-null tumors and CFT1946 in BRAF V600X cancers) that could serve as near-term proof-of-concept catalysts and re-rate the stock.
• Potential new or expanded partnership/collaboration deals that could provide non-dilutive capital and validate the TORPEDO® platform, reversing the current revenue decline trend.
• Broader sector re-rating of targeted protein degradation assets as peer clinical data matures, which could lift valuation multiples across TPD-focused biotechs including CCCC.

• Binary clinical risk: failure of any lead program (CFT8634, CFT1946) in upcoming readouts could result in severe stock drawdowns, as the pipeline is the sole source of value.
• Cash runway and dilution risk: with no revenue growth and ongoing operating losses, the company may need to raise capital at depressed prices, potentially diluting existing shareholders significantly.
• Revenue contraction of -15% YoY signals weakening collaboration economics; if partnership revenues continue to erode, operational sustainability becomes increasingly dependent on external funding or deal-making.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →